CAPTRUST Financial Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $386K | Sell |
1,021
-32
| -3% | -$11.2K | ﹤0.01% | 2443 |
|
|
2026
Q2 | $309K | Buy |
1,053
+50
| +5% | +$14.2K | ﹤0.01% | 2572 |
|
|
2026
Q1 | $280K | Buy |
1,003
+111
| +12% | +$32K | ﹤0.01% | 2438 |
|
|
2025
Q4 | $270K | Buy |
892
+20
| +2% | +$6.24K | ﹤0.01% | 2323 |
|
|
2025
Q3 | $244K | Buy |
+872
| New | +$237K | ﹤0.01% | 2307 |
|
|
2025
Q2 | – | Sell |
-7,704
| Closed | -$1.88M | – | 2517 |
|
|
2025
Q1 | $1.88M | Buy |
7,704
+1,974
| +34% | +$594K | ﹤0.01% | 938 |
|
|
2024
Q4 | $1.88M | Buy |
5,730
+4,964
| +648% | +$1.68M | 0.01% | 913 |
|
|
2024
Q3 | $256K | Sell |
766
-226
| -23% | -$71.8K | ﹤0.01% | 1974 |
|
|
2024
Q2 | $271K | Sell |
992
-695
| -41% | -$202K | ﹤0.01% | 1869 |
|
|
2024
Q1 | $584K | Sell |
1,687
-37
| -2% | -$12.2K | ﹤0.01% | 1410 |
|
|
2023
Q4 | $557K | Buy |
1,724
+97
| +6% | +$30.4K | ﹤0.01% | 1667 |
|
|
2023
Q3 | $583K | Sell |
1,627
-238
| -13% | -$91.8K | ﹤0.01% | 1552 |
|
|
2023
Q2 | $707K | Buy |
1,865
+743
| +66% | +$302K | ﹤0.01% | 1424 |
|
|
2023
Q1 | $538K | Buy |
1,122
+155
| +16% | +$72.6K | ﹤0.01% | 1372 |
|
|
2022
Q4 | $407K | Buy |
967
+194
| +25% | +$78.3K | ﹤0.01% | 1451 |
|
|
2022
Q3 | $322K | Sell |
773
-8
| -1% | -$3.99K | ﹤0.01% | 1492 |
|
|
2022
Q2 | $387K | Buy |
781
+49
| +7% | +$25.5K | ﹤0.01% | 1273 |
|
|
2022
Q1 | $412K | Buy |
732
+135
| +23% | +$81.4K | ﹤0.01% | 1246 |
|
|
2021
Q4 | $451K | Sell |
597
-89
| -13% | -$66.6K | ﹤0.01% | 1173 |
|
|
2021
Q3 | $512K | Buy |
686
+40
| +6% | +$30K | ﹤0.01% | 1020 |
|
|
2021
Q2 | $416K | Buy |
646
+46
| +8% | +$28K | ﹤0.01% | 1074 |
|
|
2021
Q1 | $343K | Buy |
600
+522
| +669% | +$309K | ﹤0.01% | 1156 |
|
|
2020
Q4 | $45K | Sell |
78
-2
| -3% | -$1.14K | ﹤0.01% | 1877 |
|
|
2020
Q3 | $42K | Buy |
80
+50
| +167% | +$25.3K | ﹤0.01% | 1692 |
|
|
2020
Q2 | $14K | Buy |
+30
| New | +$13.2K | ﹤0.01% | 2064 |
|
|
2019
Q4 | – | Sell |
-6
| Closed | -$2K | – | 1089 |
|
|
2019
Q3 | $2K | Hold |
6
| – | – | ﹤0.01% | 1784 |
|
|
2019
Q2 | $2K | Hold |
6
| – | – | ﹤0.01% | 1785 |
|
|
2019
Q1 | $2K | Hold |
6
| – | – | ﹤0.01% | 1678 |
|
|
2018
Q4 | $1K | Sell |
6
-4
| -40% | -$1.07K | ﹤0.01% | 1530 |
|
|
2018
Q3 | $3K | Sell |
10
-178
| -95% | -$55.2K | ﹤0.01% | 1430 |
|
|
2018
Q2 | $54K | Buy |
188
+10
| +6% | +$2.76K | ﹤0.01% | 660 |
|
|
2018
Q1 | $44K | Sell |
178
-108
| -38% | -$27.5K | ﹤0.01% | 635 |
|
|
2017
Q4 | $68K | Buy |
+286
| New | +$69.3K | ﹤0.01% | 521 |
|
Other funds holding BIO
CAPTRUST Financial Advisors's BIO Position: Q3 2026 in Review
CAPTRUST Financial Advisors reduced its Bio-Rad Laboratories Class A (BIO) stake by 3% in Q3 2026, selling an estimated $11.2K and leaving 1,021 shares worth $386K. The position accounts for ﹤0.01% of the portfolio, ranked #2443.
CAPTRUST Financial Advisors first reported a position in BIO in Q4 2017 and has held it in 33 quarters since. The position peaked at $1.88M in Q4 2024. 276 funds tracked by Wall St. Rank hold BIO as of Q3 2026.
- CAPTRUST Financial Advisors held 1,021 shares of Bio-Rad Laboratories Class A worth $386K as of Q3 2026.
- CAPTRUST Financial Advisors sold 32 Bio-Rad Laboratories Class A shares in Q3 2026, an estimated $11.2K.
- Bio-Rad Laboratories Class A made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q3 2026, its #2443 holding.
- CAPTRUST Financial Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2017 and has held it in 33 quarters since.
- CAPTRUST Financial Advisors's Bio-Rad Laboratories Class A position peaked at $1.88M in Q4 2024.
- 276 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2026.
Based on CAPTRUST Financial Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.